Treatment of Hyperlipedemia with Unani formulation
- Conditions
- Chronic ischemic heart disease, unspecified, Hyperlipidemia,
- Registration Number
- CTRI/2018/05/013864
- Lead Sponsor
- Central Council for Research in Unani Medicine
- Brief Summary
Hyperlipidemia is an increase in either plasma cholesterol, plasma triglycerides. Epidemiological study indicate that cholesterol level above 250 mg/100 ml. significantly raise the risk for coronary heart disease \*CHD).
Recent clinical trials show that treatment of hyperlipidemia with allopathic drugs reduces the risk for coronary heart disease. Some of the Unani drugs have the capacity to regulate lipid abnormalities. If atherosclerosis can be prevented by regulating the abnormal lipid metabolism, we may be able to manage successfully one aspect of coronary heart disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
1.Serum cholesterol: > 200 mg/dl 2.Serum Triglycerides: >150 mg / dl 3.LDL: > 115 mg/ dl 4.HDL: > 40 5.Patient should be willing to cooperate the study protocol 6.Patient should be give written informed consent 7.Patient should not have any other disease.
1.Un control diabetes mellitus 2.History of IHD 3.History of drug/alcohol abuse 4.Non cooperative patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of Serum Cholesterol and Serum Triglycerides Baseline, 1st month, 2nd month, 3rd month
- Secondary Outcome Measures
Name Time Method Safety with Pathological and biochemical tests Before and after treatment
Trial Locations
- Locations (1)
Central Research Institute of Unani Medicine
🇮🇳Hyderabad, ANDHRA PRADESH, India
Central Research Institute of Unani Medicine🇮🇳Hyderabad, ANDHRA PRADESH, IndiaDr MinhajuddinPrincipal investigator9177376011ahmedminhajuddin@yahoo.comDr S KareemullahPrincipal investigator9177376011kareemullah1757@gmail.com